by Lupus Foundation, Ohio | Sep 18, 2026 | Lupus Foundation of America, News & Events
A new study found that non-Hispanic Black individuals with systemic lupus erythematosus (SLE) experienced the highest rates of maternal cardiovascular events, maternal adverse pregnancy outcomes and infant adverse outcomes. This post was originally published on this...
by Lupus Foundation, Ohio | Sep 10, 2026 | Lupus Foundation of America, News & Events
A new investigative therapy, afimetoran, for adults with systemic lupus erythematosus (SLE) met its primary endpoint in a Phase 2 global, double-blind, randomized, dose-ranging, placebo-controlled trial (NCT04895696), showing a clear, statistically significant, and...
by Lupus Foundation, Ohio | Sep 4, 2026 | Lupus Foundation of America, News & Events
A new study comparing perspectives about disease flares in people with systemic autoimmune rheumatic diseases (SARD), like systemic lupus erythematosus (SLE), and clinicians found differences in how each recognizes a flare, especially in how quickly they begin and how...
by Lupus Foundation, Ohio | Sep 3, 2026 | Lupus Foundation of America, News & Events
A new study found two distinct biological patterns of lupus nephritis (LN), offering researchers a closer look at why kidney involvement may vary from person to person. This post was originally published on this...
by Lupus Foundation, Ohio | Aug 25, 2026 | Lupus Foundation of America, News & Events
A new study suggests that people with systemic lupus erythematosus (SLE) who have inadequate exposure to hydroxychloroquine (HCQ) may have higher estimated atherosclerotic cardiovascular (ASCVD) disease risk. This post was originally published on this...
